Annual relative increased in inpatient mortality from antimicrobial resistant nosocomial infections in Thailand

T. Phodha¹, A. Riewpaiboon¹, K. Malathum² and P. C. Coyte³

¹Faculty of Pharmacy, Mahidol University, 447 Sri-Ayuthaya Road, Rajathevi, Bangkok 10400, Thailand; ²Division of Infectious Disease, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Rajathevi, Bangkok 10400, Thailand and ³Institute of Health Policy Management and Evaluation, School of Public Health, University of Toronto Ontario, Health Sciences Building 155 College Street, Suite 425 Toronto, ON, MST 3M6, Canada

Abstract

Antimicrobial resistance is a major health threat worldwide as it brings about poorer treatment outcome and places economic burden to the society. This study aims to estimate the annual relative increased in inpatient mortality from antimicrobial resistant (AMR) nosocomial infections (NI) in Thailand. A retrospective cohort study was conducted at Ramathibodi Hospital, Bangkok, Thailand, over 2008–2012. Survival model was used to estimate the hazard ratios of mortality of AMR relative to those patients without resistance (non-AMR) after controlling for nine potential confounders. The majority of NI (73.80%) were caused by AMR bacteria over the study period. Patients in the AMR and non-AMR groups had similar baseline clinical characteristics. Relative to patients in the non-AMR group, the expected hazard ratios of mortality for patients in the AMR group with Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus were 1.92 (95% CI 0.10–35.52), 1.25 (95% CI 0.08–20.29), 1.60 (95% CI 0.13–19.10) and 1.84 (95% CI 0.04–95.58), respectively. In the complete absence of AMR bacteria, this study estimated that annually, in Thailand, there would be 111,295 fewer AMR cases and 48,258 fewer deaths.

Introduction

The discovery of antimicrobials was one of the most important medical advancements crucial to global health [1]. Antimicrobial resistance (AMR), partly related to the overuse of antimicrobial drugs, is now a common global health problem [2, 3]. Infections that were once easily cured with antimicrobial medications are now becoming more difficult, and in some cases impossible to treat effectively, resulting in premature mortality [4]. It was estimated that AMR could lead to 10 million deaths a year in 2050, globally [5]. Information regarding the relative increased in inpatient mortality due to AMR is useful to inform and motivate both change in clinical practice and policy decision making. Consequently, the purpose of this study was to estimate the relative increased in inpatient mortality from antimicrobial resistant nosocomial infections (AMR NI) in Thailand.

Methods

A retrospective cohort study was conducted at Ramathibodi Hospital, Bangkok, a 1400-bed university hospital in Thailand, between 1 January 2008 and 31 December 2012. The population of this study were patients admitted to critical areas, namely, medical intensive care unit (MICU), intermediate medical care unit (IMCU), surgical intensive care unit (SICU), cardiovascular–thoracic surgical intensive care unit, and coronary care unit (CCU) who subsequently contracted NI in either critical areas or other wards. The patients in this cohort were identified by the infection control unit of Ramathibodi Hospital using the surveillance definitions of the United States Centers for Disease Control and Prevention (US-CDC) [6]. There was no randomisation process of sample selection. Patients were categorised based on the exposure of interest including AMR and non-AMR infections in order to estimate the relative increased in inpatient mortality from antimicrobial resistant nosocomial infections (NI) in Thailand.
studied. These include pneumonia (PNI), urinary tract infection (UTI) and bloodstream infection (BSI) [9–11]. A Charlson co-morbidity index score (CCI score) was computed and assigned to each patient in order to adjust for his/her comorbidities and the severity of baseline diseases [12]. We censored the Cox model at hospital discharge. The survival time from date of infection until hospital discharge was captured by a time variable. The specimen collection date on which the symptoms were firstly noticed by the physician was chosen to represent the onset of NI [6]. The event of interest was inpatient mortality. A patient who died was treated as a failure case while a patient who was discharged alive was treated as a censored case. The hazard ratio of mortality was estimated using multivariate Cox proportional hazard model with STATA 15.0 controlling for a number of potential confounders. The certain covariates associated with inpatient mortality at $P < 0.10$ from the univariate analysis [13] were considered for backwards stepwise elimination method along with clinical considerations to construct the multivariate Cox proportional hazard model. The univariate analysis of survival function, the association among covariates, the nested model and the proportion hazard assumption (or Schoenfeld residuals) were tested [13]; see Supplementary Material for details (Supplementary Material is available on the Cambridge Core website).

The prevalence of AMR NI reported in published national surveillance [14] was used as a factor for estimating the number of AMR NI cases in a year. Then the expected annual number of deaths from AMR NI, overall and categorised by type of bacteria, was the product of the number of AMR NI cases in a year multiplied by the hazard ratios of mortality from the Cox model. The associated variance and the confidence bounds were computed to report the uncertainty of the extrapolated nationwide annual relative increased in inpatient mortality, see Supplementary Material for details (Supplementary Material is available on the Cambridge Core website).

This study protocol has been reviewed and approved by the Committee on Human Rights Related to Research Involving Human Subjects of Faculty of Medicine Ramathibodi Hospital, Mahidol University. The Institutional Review Board number for this study is ID 10-56-41. Data were anonymous, kept confidential and not linked to individuals.

**Hospital settings**

At the time of study, the hospital had nine intensive care units covering medical, surgical and paediatric populations, as well as general inpatient care units. There were 10 infection control nurses and one physician running the infection prevention and control based on the US-CDC surveillance strategies. Infection prevention measures were mainly those recommended by the US-CDC, the Society for Healthcare Epidemiology of America and WHO. The infection prevention and control programme has been performing prospective NI surveillance focusing on ICU patients continuously for decades.

**Results**

**Descriptive analysis**

Study results were reported following STROBE guideline for an observational study [15]. There were 523 patients included in this cohort. Majority of NI during the study period (73.80%) were caused by the aforementioned five species of MDR organisms. Table 1 reports the distribution of patients’ characteristics. There was an almost equal mix of males and females and most of them were elderly. Higher proportion of patients with AMR infections than those with non-AMR infections (77% vs. 58%) in the MICU, IMCU and CCU were observed. The median length of hospital stay for patients in the AMR group was longer than those in the non-AMR group. The patients in both groups were different in the distribution of CCI score. Fifty per cent of patients acquired UTI, 30% acquired PNI, 15% acquired BSI, while the remaining patients acquired multiple site of infections. Among 523 critical care inpatients with NI, 201/386 (52%) patients with AMR and 53/137 (39%) with sensitive infections died. Figure 1 reports the number of cases with NI over 2008–2012. NI caused by *A. baumannii*, *E. coli*, *K. pneumoniae* and *S. aureus* had a greater proportion of AMR than non-AMR infections but *P. aeruginosa* had a smaller proportion of AMR than non-AMR infections.

**Survival analysis**

Hazard ratios of inpatient mortality and 95% confidence bounds for covariates in the Cox proportional hazard regression model were reported in Table 2. Patients in the AMR group had a greater chance to die by 32% relative to those patients in the non-AMR group. There was no significant increase in the hazard of inpatient mortality related to AMR, for all tested bacteria. Hazard ratios were estimated to be 1.92 (95% CI 0.10–35.52), 1.25 (95% CI 0.08–20.29), 1.60 (95% CI 0.13–19.10) and 1.84 (95% CI 0.04–95.58) for *A. baumannii*, *E. coli*, *P. aeruginosa* and *S. aureus*, respectively. The other covariates adjusting for the Cox model comprised of sex, admitted ward, CCI score, site of infection, number of NI episode and the interaction effects between CCI score and site of infection.

**Nationwide annual relative increased in-hospital mortality from AMR NI in Thailand**

The estimated nationwide annual relative increased in inpatient mortality from AMR NI in Thailand was reported in Table 3. This study estimated that around 111 295 AMR NI cases occurred in several types of hospitals in Thailand and 48 258 deaths in 2012. Resistant *A. baumannii* was the most common cause of death. About 60 000 cases with resistant *A. baumannii* infections accounted for almost 40 000 deaths in that year.

**Discussions**

We found that almost three-quarters of all patients with NI acquired resistant bacterial infections over the study period. The number of cases with AMR NI in our study was consistent with findings in a recent study in Thailand [16]. The distribution of the type of bacterial infections was also in accordance with the national antimicrobial Surveillance Center (NARST) [17]. The relative increased in inpatient mortality from AMR NI was estimated using a survival analysis controlling for confounding factors [18–21], including CCI score in order to adjust patients’ clinical baseline as other recent studies had done [22–24]. Compared with patients in the non-AMR group, the mortality chances for patients in the AMR group with *A. baumannii*, *E. coli*, *P. aeruginosa* and *S. aureus* were 92%, 25%, 60% and 84% higher, respectively. Because resistant *E. coli* in our study was ESBL-producing organisms which can be
treated by widely available carbapenem antimicrobials, mortality of infection caused by this bacteria remained low. Another explanation is that the most common site of \textit{E. coli} infection was UTI, which generally is not significantly associated with fatal outcome. On the other hand, \textit{A. baumannii} mostly causes infection of the respiratory system which tends to carry higher mortality background. Only a few antimicrobial agents such as colistin, a nephrotoxic agent and tigecycline, a bacteriostatic agent with unpromising efficacy in the literature, are available for treatment. As a result, mortality associated with \textit{A. baumannii} infection in our study was high. There were several studies that reported the mortality chances of these bacterial infections in Thailand and worldwide. Lim \textit{et al.} published in 2016 \cite{Lim2016} estimated the mortality attributable to multidrug resistance in hospital-acquired infection in Thailand for \textit{A. baumannii}, \textit{E. coli}, \textit{P. aeruginosa} and \textit{S. aureus} as 70%, 19%, 65% and 44%, respectively. Yang \textit{et al.} published in 2013 \cite{Yang2013}, a retrospective

| Table 1. Descriptive analysis, n (%) or median (IQR) |
|-----------------------------------------------------|
| **Patient’s characteristics** | **Susceptibility** |
| | AMR | Non-AMR |
| | 386 (73.80) | 137 (26.20) |
| Gender | | |
| Male sex | 185 (47.93) | 58 (42.34) |
| Age (years), median (IQR) | 69 (56–81) | 66 (48–79) |
| Admitted ward | | |
| Surgical ICU | 63 (16.32) | 41 (29.33) |
| Cardiovascular–thoracic surgical ICU | 26 (6.74) | 17 (12.41) |
| Intermediate medical care unit | 187 (48.45) | 47 (34.31) |
| Coronary care unit | 26 (6.74) | 20 (14.60) |
| Medical ICU | 84 (21.76) | 12 (8.76) |
| LOS (days), median (IQR) | 43 (27–67) | 37 (24–65) |
| Mortality adjusted LOS (days), median (IQR) | 51 (33–74) | 39 (24–68) |
| Number of NI episode, mean ± S.D. | 1.10 ± 0.31 | 1.01 ± 0.09 |
| Charlson co-morbidity index score | | |
| 0 | 42 (10.88) | 12 (8.76) |
| 1 | 44 (11.40) | 26 (18.98) |
| 2 | 63 (16.32) | 34 (24.82) |
| 3 | 62 (16.06) | 19 (13.87) |
| 4 | 67 (17.36) | 20 (14.60) |
| 5 | 39 (10.10) | 11 (8.03) |
| 6 | 69 (17.88) | 15 (10.95) |
| Site of infection | | |
| UTI | 174 (45.08) | 71 (51.82) |
| Pneumonia | 112 (29.02) | 36 (26.28) |
| BSI | 50 (12.95) | 23 (16.79) |
| More than one site of infection | 50 (12.95) | 7 (5.11) |
| Discharge status | | |
| Dead | 201 (52.07) | 53 (38.69) |
| Survive | 185 (47.93) | 84 (61.31) |
| Organismsa | 489 (100) | 254 (100) |
| \textit{Acinetobacter baumannii} | 219 (44.79) | 38 (14.96) |
| \textit{Escherichia coli} | 112 (22.90) | 55 (21.65) |
| \textit{Klebsiella pneumoniae} | 73 (14.93) | 48 (18.90) |
| \textit{Pseudomonas aeruginosa} | 29 (5.93) | 110 (43.31) |
| \textit{Staphylococcus aureus} | 56 (11.45) | 3 (1.18) |

\*Multiple conditions.
10-year study was conducted at a 2900-bed teaching hospital located in Northern Taiwan, reported crude 14-day mortality rates of A. baumannii in hospital-acquired PNI and ventilator-associated PNI were 43.8% and 31.3%, respectively. Huang et al. published in 2012 [21], a retrospective cohort study was conducted in Taipei Veterans General Hospital, Taiwan, estimated odd ratio of mortality caused by carbapenem-resistant A. baumannii bacteraemia was 1.03 (95% CI 0.48–2.20) relative to carbapenem-susceptible A. baumannii bacteraemia. Abernethy et al. published in 2015 [25], a large national study in England, reported a 30-day all-cause mortality rate of E. coli was 18.2% (95% CI 17.8–18.7%). Schreiber et al. published in 2011 [19] reported the mortality rate in patients with bacteraemia complicated S. aureus PNI was 39% compared with non-bacteria. The meta-analysis of Cosgrove et al. published in 2003 [26], enrolled studies between January 1980 and December 2000 reported a significant increase in odd ratio (1.93; 95% CI 1.54–2.42; P < 0.001) of mortality associated with methicillin-resistant S. aureus bacteraemia compared with methicillin-susceptible S. aureus bacteraemia. Our study estimated higher expected hazard ratios of mortality for AMR NI relative to non-AMR NI than other studies. Overall, mortality of AMR NI in our study was not statistically significant different from those of non-AMR. It might be due to the fact that these patients were all critically ill which posed them at risk of dying. Furthermore, with relatively more available resources for treatment as compared with other non-teaching hospitals, mortality of AMR NI might be lowered as shown by some studies that effective antibiotics played an important role in improving outcomes of these infections [27, 28].

This study estimated that the annual relative increased in inpatient mortality in Thailand would be 48 258 cases out of 111 295 (over 50%) cases with AMR NI. The study of Lim et al. published in 2016 [16] estimated the burden of MDR bacteria in Thailand to be 19 122 of 45 209 (43%) deaths in 2010. The preliminary study of health and economic impact of AMR in Thailand published in 2012 [14] found 38 481 additional deaths of 87 481 (43%) AMR cases in 2010. However, our annual number of deaths is higher than those reported by others. We identified the annual number of deaths as the relative difference hazard ratio of mortality for the AMR and non-AMR groups based on the Cox model fitted with individual-level data of our study samples. To the best of our knowledge, this is the most updated data collected from patients in Thailand. The conditional mortality on having AMR was derived using the hazard ratio of mortality provided by the Cox model. Kritsotakis et al. in 2017 [11] also used the multivariate Cox proportional hazard model to estimate hazard of death between patients with hospital-acquired infections and uninfected patients in terms of adjusted hazard ratios and associated 95% confidence bounds. Even though, Lim et al. in 2016 [16] used a 30-day all-cause mortality rate while the preliminary study in 2012 [14] used a decision tree model. Moreover, our study took place in the critical care units of a large tertiary hospital. Most of the patients in our study had more severe illnesses than other hospital types. Consequently, the samples used may not necessarily be representative of the whole NI population in Thailand. This may result in an overestimate of AMR burden estimation for all hospitalised patients in the country. However, to the best of our knowledge, hospital-acquired infection surveillance in most hospitals in Thailand now focus on the ICU population according to targeted surveillance strategies.

Limitations

There are four main study limitations comprising the selection of an appropriate comparator, the lack of adjustment for acute severity of illness parameters, the potential statistical challenges to the estimation and the lack of accounting for the competing risk of being discharged in the multivariate Cox proportional hazard regression model. First, we have taken the more conservative approach of assuming that resistant infections are replacing susceptible ones so that we used the susceptible ones as comparators. The majority of studies to date have compared outcomes in patients infected with the resistant strain of an organism with patients infected with the susceptible strain of the same organism [7]. We did not have patients with no infection as comparator to deal with the competing risk of infection (susceptible and resistant, which might differ) and death. Engemann et al. in 2003 [29] compared outcomes among patients with resistant infections to uninfected control subjects selected on the basis of specific criteria which assesses the burden of having a resistant infection.
rather than no infection. The latter type of comparison results in a much higher estimate of adverse events attributable to resistance [7]. Second, acute severity of illness scores and their use in predicting outcomes have gained considerable interest for predicting ICU and in-hospital mortality [30]. The data on the physiologic measurements for severity of illness score calculation were incomplete. The results of this study might overestimate the impact of AMR infection due to the lack of adjustment for acute severity of illness parameters. Third, the AMR status was treated as an independent variable in the multivariate Cox proportional hazard regression model. We did not address the endogeneity of AMR status. It is possible that variables correlated with

Table 2. Multivariate cox proportional hazard regression model

| Predictor variables                                      | HR of in-hospital death | 95% CI      | p-value  |
|----------------------------------------------------------|-------------------------|-------------|----------|
| Gender                                                   |                         |             |          |
| Female                                                   | 1                       | 1           |          |
| Male                                                     | 1.23                    | 0.95–1.59   | 0.129    |
| Admitted ward                                            |                         |             |          |
| Intermediate medical care unit                           | 1                       | 1           |          |
| SICU and cardiovascular–thoracic surgical ICU            | 0.65                    | 0.47–0.91   | 0.012    |
| Coronary care unit and medical ICU                       | 1.42                    | 1.06–1.92   | 0.020    |
| CCI score                                                |                         |             |          |
| 0–2                                                      | 1                       | 1           |          |
| ≥3                                                       | 1.42                    | 0.87–2.32   | 0.000    |
| Site of infection                                        |                         |             | 0.1638   |
| UTI                                                      | 1                       | 1           |          |
| Pneumonia                                                | 1.60                    | 0.85–3.01   | 0.142    |
| BSI                                                      | 1.29                    | 0.59–2.85   | 0.528    |
| More than one site of infection                          | 2.58                    | 1.09–6.12   | 0.032    |
| Number of NI episode                                     | 0.51                    | 0.31–0.85   | 0.010    |
| Susceptibility                                           |                         |             |          |
| Non-AMR                                                  | 1                       | 1           |          |
| AMR                                                      | 1.32                    | 0.67–2.61   | 0.419    |
| Organisms                                                |                         |             | 0.4444   |
| More than one organisms                                   | 1                       | 1           |          |
| A. baumannii                                             | 0.69                    | 0.23–2.07   | 0.509    |
| E. coli                                                  | 1.31                    | 0.48–3.53   | 0.600    |
| K. pneumoniae                                            | 1.35                    | 0.52–3.47   | 0.536    |
| P. aeruginosa                                            | 1.80                    | 0.84–3.90   | 0.134    |
| S. aureus                                                | 1.64                    | 0.34–7.92   | 0.538    |
| Susceptibility – organism                                |                         |             |          |
| Non-AMR                                                  | 1                       | 1           |          |
| AMR – A. baumannii                                       | 1.92                    | 0.10–35.52  | 0.208    |
| AMR – E. coli                                            | 1.25                    | 0.08–20.29  | 0.568    |
| AMR – K. pneumoniae                                      | 0.84                    | 0.05–13.74  | 0.205    |
| AMR – P. aeruginosa                                      | 1.60                    | 0.13–19.10  | 0.442    |
| AMR – S. aureus                                          | 1.84                    | 0.04–95.58  | 0.845    |
| Charlson co-morbidity score – site of infection          |                         |             | 0.2971   |
| CCI score = 0–2                                          | 1                       | 1           |          |
| CCI score ≥3 with pneumonia                              | 1.55                    | 0.57–21.76  | 0.217    |
| CCI score ≥3 with BSI                                    | 1.80                    | 0.37–29.08  | 0.201    |
| CCI score ≥3 with more than 1 site of infection          | 0.80                    | 0.30–28.22  | 0.635    |

https://doi.org/10.1017/S0950268818003436 Published online by Cambridge University Press
AMR status may also be related to death. In the absence of controls for potential endogeneity bias, the estimated impact of AMR status on relative increased in inpatient mortality may be overestimated. Additionally, statistical power may not have been reached due to limited sample size for certain susceptibility group. Finally, in-hospital mortality was used, and therefore using Cox proportional hazards methods on such an outcome may have issues—such as not accounting for the competing risk of being discharged and overall mortality wherein mortality after discharge is included.

**Summary**

AMR has become a major public health threat and is spreading worldwide. Infectious diseases are the second main cause of death in low- to middle-income countries. This study sought to estimate the relative increased in inpatient mortality from AMR NI in Thailand to non-AMR NI using a multivariate Cox proportional hazard regression model. The Cox modelling was controlled for nine potential confounders while the AMR group has an elevated risk of inpatient mortality by 32%, it is not significant. In the absence of AMR bacteria, this study estimated that annually there would be 111,295 fewer AMR cases and 48,258 fewer deaths. The findings will assist in informing policy decision makers in their enactment of Thailand’s National Strategic Plan on Antimicrobial Resistance for 2017–2021.

**Supplementary material.** The supplementary material for this article can be found at https://doi.org/10.1017/S0950268818003436.

**Author ORCIDs.** K. Malathum 0000-0002-3186-638X

**Acknowledgement.** This publication fulfils a part of the degree programme of Doctor of Philosophy (Pharmacy Administration), Faculty of Graduate Studies, Mahidol University. We are grateful to the Ramathibodi Hospital for supporting and facilitating the study. We would like to express our appreciation to Associate Professor Yoel Lubell, University of Oxford and Mahidol Oxford Tropical Medicine Research Unit for reviewing this manuscript.

**Financial support.** This work was supported by the Thailand Research Fund through the Royal Golden Jubilee Ph.D. Program (Grant No. PHD/0276/2551).

**Conflict of interest.** None.

**References**

1. Laxminarayan R et al. (2016) Access to effective antimicrobials: a worldwide challenge. *The Lancet* 387, 168–175.
2. Laxminarayan R et al. (2013) Antibiotic resistance – the need for global solutions. *The Lancet Infectious Diseases* 13, 1057–1098.
3. World Health Organization (2014) Antimicrobial resistance: Global Report on surveillance. Available at http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1 (Accessed 25 June 2017).
4. Infectious Diseases Society of America (2004) Bad bugs, no drugs as antibiotic discovery stagnates a public health crisis brews. *Resistance on the rise*. Virginia: Infectious Diseases Society of America, July 2004. pp. 9–12.

---

**Table 3. Annual relative increased in-hospital mortality from AMR NI**

| (A) Annual number of AMR NI | Bacteria      | Proportion of NI | NI cases | Proportion of AMR NI | Variance of proportion of AMR NI | AMR NI cases |
|----------------------------|---------------|------------------|----------|----------------------|----------------------------------|--------------|
| Acinetobacter baumannii    | 0.47          | 70 065           | 0.88     | 0.11                 | 61 412                           |
| Escherichia coli           | 0.31          | 46 720           | 0.72     | 0.20                 | 33 742                           |
| Klebsiella pneumoniae      | 0.23          | 34 022           | 0.73     | 0.20                 | 24 796                           |
| Pseudomonas aeruginosa     | 0.25          | 37 777           | 0.57     | 0.24                 | 21 628                           |
| Staphylococcus aureus      | 0.11          | 16 152           | 0.96     | 0.04                 | 15 576                           |
| All AMR                    | 1             | 150 806          | 0.74     | 0.19                 | 111 295                          |

| (B) Annual number of deaths attributable to AMR NI | Bacteria      | Conditional mortality rate on having AMR | Variance of conditional mortality rate on having AMR | Overall AMR mortality | Variance of annual number of AMR mortality | 95% CI of variance of annual number of AMR mortality |
|--------------------------------------------------|---------------|-----------------------------------------|--------------------------------------------------|----------------------|--------------------------------------------|--------------------------------------------------|
| Acinetobacter baumannii                          | 0.61          | 0.90                                    | 37 462                                           | 15 253               | 37 461–37 463                           |
| Escherichia coli                                 | 0.56          | 0.78                                    | 18 895                                           | 1153                 | 18 895–18 896                          |
| Klebsiella pneumoniae                            | 0.19          | 0.72                                    | 4712                                             | 773                  | 4711–4713                              |
| Pseudomonas aeruginosa                           | 1.40          | 0.61                                    | 30 279                                           | 1116                 | 30 279–30 280                          |
| Staphylococcus aureus                            | 1.49          | 1.62                                    | 23 208                                           | 1794                 | 23 208–23 209                          |
| All AMR                                         | 0.32          | 0.13                                    | 48 258                                           | 4661                 | 48 257–48 259                          |

T. Phodha et al. https://doi.org/10.1017/S0950268818003436 Published online by Cambridge University Press
5. O’Neill J (2014) Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on antimicrobial resistance. Available at https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (Accessed 12 February 2018).

6. Horan TC, Andrus M and Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control 36, 309–332.

7. Cosgrove SE et al. (2003) The impact of antimicrobial resistance on health and economic outcomes. Clinical Infectious Diseases 36, 1433–1437.

8. de Kraker MEA et al. (2011) Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. Journal of Antimicrobial Chemotherapy 66, 398–407.

9. World Health Organization (2011) Report on the burden of endemic health care-associated infection worldwide. Available at http://apps.who.int/iris/bitstream/handle/10665/80135/9789241501507_eng.pdf?sequence=1 (Accessed 13 August 2017).

10. Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial infections: no ESKAPE. Journal of Infectious Diseases 197, 1079–1081.

11. Kritsotakis EI et al. (2017) Prevalence, incidence burden, and clinical impact of healthcare-associated infections and antimicrobial resistance: a national prevalent cohort study in acute care hospitals in Greece. Infection and drug Resistance 10, 317–328.

12. Charlson ME and Carmeli Y (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40, 373–383.

13. Institute for Digital Research and Education, University of California (2017) Survival analysis with STATA. Available at http://stats.idre.ucla.edu/stata/seminars/stata-survival/ (Accessed 11 May 2017).

14. Phumart P et al. (2012) Health and economic impacts of antimicrobial resistant infections in Thailand: a preliminary study. Journal of Health Systems Research 6, 352–360.

15. Vandenbroucke JP et al. (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18, 805–835.

16. Lim C et al. (2016) Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife 5, 1–18.

17. National Antimicrobial Resistance Surveillance Centre Thailand (2017) Antibiograms. Available at http://narst.dmec.moph.go.th/antibiograms.html (Accessed 25 January 2018).

18. Shurland S et al. (2007) Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infection Control and Hospital Epidemiology 28, 273–279.

19. Schreiber MP, Chan CM and Shorr AF (2011) Bacteremia in Staphylococcus aureus pneumonia: outcomes and epidemiology. Journal of Critical Care 26, 395–401.

20. Rodriguez-Bano J et al. (2012) Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clinical Infectious Diseases 54, 167–174.

21. Huang S-T et al. (2012) Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Journal of Microbiology, Immunology and Infection 45, 356–362.

22. Pena C et al. (2012) Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemotherapy 56, 1265–1272.

23. Yang Y-S et al. (2013) Acinetobacter baumannii nosocomial pneumonia: is the outcome more favorable in non-ventilated than ventilated patients? BMC Infectious Diseases 13, 1–8.

24. Nguyen M-L et al. (2015) Risk factors for and outcomes of bacteremia caused by extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella species at Canadian tertiary care hospital. The Canadian Journal of Hospital Pharmacy 68, 136–143.

25. Abernethy JK et al. (2015) Thirty day all-cause mortality in patients with Escherichia coli bacteremia in England. Clinical Microbiology and Infection 21, 251–258.

26. Cosgrove SE et al. (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clinical Infectious Diseases 36, 53–59.

27. Wang Q et al. (2016) Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. European Journal of Clinical Microbiology & Infectious Diseases 35, 1–11.

28. Gutiérrez-Gutiérrez BN et al. (2017) Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. The Lancet Infectious Diseases 17, 726–734.

29. Engemann JJ et al. (2003) Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clinical Infectious Diseases 36, 592–598.

30. Johnson AEW, Kramer AA and Clifford GD (2013) A new severity of illness scale using a subset of acute physiology and chronic health evaluation data elements shows comparable predictive accuracy. Critical Care Medicine 41, 1711–1718.